Background {#Sec1}
==========

Patients with acute kidney injury (AKI) have increased mortality, prolonged hospital stay and accelerated progression to chronic kidney disease (CKD) \[[@CR1]\]. AKI is associated with high morbidity and mortality despite advances in modern medical care \[[@CR2], [@CR3]\]. Early and exact detection of potentially significant AKI is important in clinical practice and could lead to timely management \[[@CR4]\]. Serum creatinine has traditionally served as a surrogate of renal function, despite its limitations as a diagnostic predictor of AKI \[[@CR5]\]. The limitations of serum creatinine include a lack of steady-state conditions in critically ill patients, with the determinants of serum creatinine (rate of production, apparent volume of distribution and rate of elimination) being variable in the ICU setting.

Novel biomarkers can detect renal tubular injury earlier than serum creatinine in the setting of AKI \[[@CR6]--[@CR8]\]. As these markers correlate with renal tubular injury or function, their concentrations in urine over time, alone or in combination, could provide important information on the progression of AKI \[[@CR9]\]. However, most of those patients who develop AKI experience a milder form of AKI (e.g., Kidney Disease: Improving Global Outcomes (KDIGO) stage 1) with transient shifts in serum creatinine, and do not progress to more advanced stages of AKI (KDIGO stage 2 or 3) or require acute dialysis \[[@CR10]--[@CR12]\]. Whereas previous studies have attempted to predict AKI (defined as worsening of KDIGO stage) rather than immediate assessment after potential kidney insult, a panel of biomarkers could be used to predict progression of AKI to advanced AKI or mortality among patients after kidney injury (e.g., cardiovascular surgery) \[[@CR10], [@CR13], [@CR14]\]. Therefore, we validated three urinary markers extensively upregulated in renal proximal tubules in response to ischemia-reperfusion AKI: urinary hemojuvelin (uHJV) \[[@CR8]\], urinary kidney injury molecule-1 (uKIM-1) \[[@CR15]\] and urinary α-glutathione S-transferase (uα-GST) \[[@CR16]\], and one marker of distal tubule damage, urinary π-glutathione S-transferase (uπ-GST) \[[@CR16]\] (see Additional file [1](#MOESM1){ref-type="media"}). We further measured urinary neutrophil gelatinase-associated lipocalin (uNGAL), the well-studied and established inflammatory biomarker identified both in proximal and distal renal tubular damage \[[@CR17]\], to validate the prediction of AKI following sequential biomarker measurements after cardiovascular surgery.

Moreover, multiple AKI severity scores have also been derived to predict patient outcome \[[@CR18]\]. We further compared the contribution of the clinical models of Liano's score (see Additional file [1](#MOESM1){ref-type="media"}) \[[@CR19]\], Cleveland Clinic acute renal failure score \[[@CR20]\], and Sequential Organ Failure Assessment (SOFA) score \[[@CR21]\], and combined these with the predictive power of the urinary biomarkers in an effort to identify and validate the best prediction model for advanced AKI and composite outcomes in patients undergoing cardiovascular surgery.

We hypothesized that some combinations of clinical scores and these site-orientated renal biomarkers would provide better diagnostic accuracy than either alone. In addition, these combinations might involve biomarkers that reflect differing aspects of the pathogenesis of advanced AKI in this population.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study was conducted by the biomarker investigation group from the National Taiwan University Study Group on Acute Renal Failure (NSARF) (see Additional file [1](#MOESM1){ref-type="media"}), using a multicenter, prospectively constructed database of AKI \[[@CR22]--[@CR26]\]. Patients undergoing cardiovascular surgery (including coronary bypass, valvular operations and aortic aneurysm repair) between August 2009 and December 2014, were enrolled prospectively from a tertiary center in northern Taiwan and two regional hospitals in central and northern Taiwan. Patients with the following conditions were excluded: those who were younger than 18 years of age, those who were diagnosed with AKI under the KDIGO definitions during index hospitalization before surgery, those who had undergone renal replacement therapy, those who had a history of nephrectomy or renal transplantation and estimated glomerular filtration rate (eGFR) \< 30 mL/1.73 m^2^ at the time of ICU enrollment. The enrollee was required to have a baseline serum creatinine measurement, defined as 7--180 days prior to the index hospital admission.

Ethics and consent {#Sec4}
------------------

This study was approved by the research ethics review board of National Taiwan University Hospital (201105040RC) along with established written informed consent. This research was carried out in accordance with the approved guidelines. Written informed consent was obtained from all participants before inclusion. This study was conducted in accordance with the Declaration of Helsinki.

Clinical data collection {#Sec5}
------------------------

Medical records of study participants were prospectively reviewed to retrieve hospitalization data, including baseline demographic characteristics (Table [1](#Tab1){ref-type="table"}), intervention procedures, and comorbidity status. Creatinine level with the accompanying eGFR (through the Modification of Diet in Renal Disease (MDRD) Study equation formula) was used for eGFR in this study. Among adults, the MDRD Study equation provides a clinically useful estimate of GFR in patients with stable kidney status \[[@CR27]\]; urine output was recorded at each time point after surgery as detailed in the study protocol. Postoperative inotropic agent use was quantified as per inotropic equivalents (see Additional file [1](#MOESM1){ref-type="media"}) \[[@CR23], [@CR25], [@CR28]\]. Surgery-related parameters included surgical methods, aortic clamping time and cardiopulmonary bypass time. Lengths of total admission and ICU admission were also recorded. Disease severity was evaluated as post-surgical SOFA score. The clinical classifications of Liano's score \[[@CR19]\] and Cleveland Clinic Foundation Acute Renal Failure Scoring System (CCF ARF score) \[[@CR20]\] were also assessed to examine the risk of postoperative renal failure. Clinical and demographic characteristics of these patients were collected at each site on a case report form, which was sent to the coordinating center for entry into the NSARF database \[[@CR29]--[@CR31]\].Table 1Summary of baseline and clinical characteristics of the study patientsAllNo AKI or stage 1 AKIStage 2 or 3 AKI*p* value(*n* = 149)(*n* = 131)(*n* = 18)Patient characteristics Age62.36 ± 13.6462.32 ± 13.6262.72 ± 14.230.907 Gender (male)104 (69.8%)95 (72.5%)9 (50.0%)0.051 BMI24.87 ± 3.7324.82 ± 3.4825.26 ± 5.330.735Comorbidities Hypertension77 (51.7%)69 (52.7%)8 (44.4%)0.512 Diabetes mellitus36 (24.2%)32 (24.4%)4 (22.2%)0.838 COPD4 (2.7%)4 (3.1%)0 (0.0%)0.452 Liver cirrhosis4 (2.7%)4 (3.1%)0 (0.0%)0.452 Congestive heart failure14 (9.4%)14 (10.7%)0 (0.0%)0.145 Malignancy5 (3.4%)4 (3.1%)1 (5.6%)0.58Laboratory data at admission Preoperative creatinine (mg/dL)1.18 ± 0.331.17 ± 0.311.26 ± 0.430.388 eGFR (MDRD) (mL/min/1.73 m^2^)63.27 ± 20.5963.86 ± 20.2958.97 ± 22.850.346 eGFR between 30 and 60 mL/min/1.73 m^2^63 (42.3%)56 (42.7%)7 (38.9%)0.756 Hemoglobin (g/dL)13.02 ± 2.0213.18 ± 1.9611.83 ± 2.170.007\* Albumin (g/dL)4.15 ± 0.634.26 ± 0.473.40 ± 1.030.003\* LVEF \< 55%35 (23.5%)31 (23.7%)4 (22.2%)0.892 LVEF \< 35%10 (6.7%)9 (6.9%)1 (5.6%)0.834Perioperative condition Inotropic equivalents5.83 ± 6.614.82 ± 4.4513.10 ± 12.810.014\* Presence of CPB93 (62.4%)81 (61.8%)12 (66.7%)0.691 CPB time (min)106.57 ± 98.87102.23 ± 97.43143.27 ± 111.960.200 Presence of cross clamp72 (48.3%)63 (48.1%)9 (50.0%)0.879 Clamp time (min)57.41 ± 65.1155.66 ± 65.1878.20 ± 63.820.295Operative method CABG77 (51.7%)70 (53.4%)7 (38.9%)0.247 Valve64 (43.0%)55 (42.0%)9 (50.0%)0.519 Aorta20 (13.4%)16 (12.2%)4 (22.2%)0.243Post-surgery SOFA score6.14 ± 2.965.84 ± 2.698.47 ± 3.920.015\*  Respiratory0.67 ± 0.750.66 ± 0.730.77 ± 1.010.608  Coagulation0.43 ± 0.600.40 ± 0.570.69 ± 0.850.093  Liver0.87 ± 0.650.85 ± 0.641.00 ± 0.710.432  Cardiovascular0.28 ± 0.550.24 ± 0.480.62 ± 0.960.191  Central nervous system3.08 ± 1.203.08 ± 1.213.08 ± 1.120.997  Renal function0.72 ± 0.790.58 ± 0.662.07 ± 0.64\< 0.001\* Cleveland score3.80 ± 1.623.79 ± 1.563.89 ± 2.030.802 Liano's score−0.60 ± 0.84−0.61 ± 0.84−0.47 ± 0.870.506 Length of admission (days)18.69 ± 37.6217.56 ± 38.5130.75 ± 24.410.247 Length of ICU admission (days)3.55 ± 3.303.43 ± 2.847.64 ± 5.350.027\* 90-day mortality16 (10.7%)6 (4.6%)10 (55.6%)\< 0.001\*Values are mean ± SD or number (percentage)*AKI* acute kidney injury, *BMI* body mass index, *CABG* coronary artery bypass graft, *COPD* chronic obstructive pulmonary disease, *CPB* cardiopulmonary bypass, *eGFR* estimated glomerular filtration rate, *ICU* intensive care unit, *LVEF* left ventricular ejection fraction, *MDRD* Modification of Diet in Renal Disease Study equation, *SOFA score* Sequential Organ Failure Assessment score\**p* \< 0.05

Sample collection {#Sec6}
-----------------

Fresh urine samples were obtained in the ICU at 0, 3, 6, 12 and 24 h after completion of surgery. Other laboratory examinations were performed as indicated clinically. Urine specimens were collected by a standardized procedure, centrifuged within 1 h and the sediments discarded. The urine samples, collected in separate polypropylene tubes containing sodium azide, were stored at − 80 °C until required. Each specimen was centrifuged (800 g at 4 °C for 5 min) and the supernatant was collected for ELISA.

Biomarker Measurements {#Sec7}
----------------------

The urinary HJV, KIM-1 and NGAL levels were measured by a human hemojuvelin ELISA kit (USCN Life Science, Inc., Wuhan, China), human urinary TIM-1/KIM-1/HAVCR Quantikine ELISA kit (R&D Systems, USA) and a human lipocalin-2/NGAL ELISA kit (R&D Systems), respectively. All of the results were expressed in nanograms per milliliter. The lower limit of detection for HJV, KIM-1 and NGAL was 0.156, 0.046 and 0.2 ng/mL, respectively. The urinary α-GST and π-GST levels were determined using Human Alpha and Pi GST EIA Test Kits (EKF Diagnostics). The results were expressed in micrograms per liter. The inter-assay and intra-assay coefficient of variation for α-GST was 6.3% and 2.7%, respectively, and for π-GST, it was 8.6% and 3.1%, respectively. The lower limit of detection for α-GST and for π-GST was 0.3 μg/L. Assays were completed as described by the manufacturer's protocol, and each measurement was performed in duplicate. Urinary creatinine levels were measured using the Jaffe assay, with standardization to isotope dilution mass spectrometry (IDMS)-traceable reference. Technicians performing the biomarker measurements were blinded to each patient's clinical information. All biomarkers were measured from frozen aliquots that did not undergo any additional freeze--thaw cycles.

Outcome definitions {#Sec8}
-------------------

The clinical primary endpoint was defined as the development of advanced AKI (stage 2 or 3, specified by the KDIGO criteria \[[@CR32]\]), with both urine and creatinine criteria applied. The secondary outcomes were 90-day mortality after hospital discharge and composite outcomes defined as 90-day mortality after hospital discharge or advanced AKI, whichever occurred earlier.

Statistical analysis {#Sec9}
--------------------

All analyses were performed using SPSS software, version 20 (IBM, Armonk, NY, USA), R software, version 3.2.2 (Free Software Foundation, Inc., Boston, MA, USA), and MedCalc Statistical Software, version 15.11.3 (MedCalc Software bvba, Ostend, Belgium; <https://www.medcalc.org>; 2015). The two-sample *t* test or Mann--Whitney rank sum test was used as appropriate to compare continuous variables; for categorical variables, the chi-square (χ2) or Fisher's exact test was applied. Friedman two-way analysis of variance (ANOVA) was used to assess the overall difference in HJV, KIM-1, NGAL, α-GST and π-GST between the "no AKI or stage 1 AKI" and the "stage 2 or 3 AKI" groups at 0, 3, 6, 12 and 24 h after cardiovascular surgery \[[@CR33]\]. We normalized biomarker levels with urine creatinine concentrations and analyzed them at each time point \[[@CR34]\]. We fitted logistic regression models to examine the association between each marker (urinary NGAL, HJV, KIM-1, α-GST and π-GST) and advanced AKI, and generated an area under the receiver-operating characteristic (ROC) curve to assess the predictive accuracy of each marker. Power analysis was conducted based on the prior knowledge that the ratio of cases to controls was 4:1. We required 105 patients (21 with severe AKI and 84 without severe AKI) to achieve power of 0.8, with type I error of 0.05. This was based on the preliminary knowledge that the discriminatory power of urinary HJV to predict severe AKI was 0.7 \[[@CR35]\]. We used a generalized additive model (GAM) (with spline) incorporating the subject-specific (longitudinal) random effects and adjusted for other clinical parameters to predict the outcomes \[[@CR36], [@CR37]\]. Simple and multiple generalized additive models (GAMs) were fitted to detect nonlinear effects of continuous covariates and identify appropriate cutoff point(s) for discretizing continuous covariates, if necessary, during the stepwise variable selection procedure. We defined the optimal cutoff value as odd equals to zero \[[@CR38]\].

To assess the additive prediction ability of each biomarker compared with traditional clinical predictors, we identified clinical risk prediction models (including Liano's score, CCF ARF score and SOFA score) that were based on area under the curve (AUC) analysis and then added each biomarker individually to this clinical model. We estimated the risk score function using a logistic regression model including clinical and biomarker variables as covariates. The Hosmer-Lemeshow logistic regression model test for goodness of fit was used to assess the calibration between the current model and the expected model. Finally, we calculated the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) to estimate overall improvement in reclassification with urinary biomarkers adding to clinical variables \[[@CR39]\]. We reclassified the patients who developed advanced AKI using 0--12%, 12--30% and \> 30% for the risk categories. A *p* value \<0.05 was considered significant.

Hierarchical clustering analysis was performed using the cluster program and the results were visualized using the Treeview program \[[@CR40]\]. The biomarkers were arranged in such a way that the most similar expression profiles were placed next to each other. In the color scheme, strong positive staining is indicated as a red cube, weak positive staining as a black cube and negative staining as a green cube. Absence of staining data is indicated with a grey cube.

Results {#Sec10}
=======

Clinical characteristics {#Sec11}
------------------------

A total of 149 patients who underwent cardiovascular surgery were enrolled in this study, with subsequent time-varying sample collection. There were 46 patients who had AKI episodes as defined by KDIGO criteria (30.9%), with 28 (18.8%) having stage 1 AKI, 11 (7.4%) stage 2 AKI, and 7 (4.7%) progressing to stage 3 AKI: 6 patients progressed to dialysis-dependent AKI in the advanced AKI group. The 90-day mortality rate in this cohort was 10.7%. The clinical characteristics of patients with and without advanced AKI are described in Table [1](#Tab1){ref-type="table"}. Patients who developed advanced AKI had lower hemoglobin and albumin levels, were administered higher inotropic equivalents and had higher SOFA scores. However, there were no statistical differences between patients with and without advanced AKI with respect to age, gender, body mass index (BMI), comorbidities, baseline kidney function, baseline chronic kidney disease (eGFR between 30 and 60 ml/min/1.73 m^2^) status and the Liano and CCF ARF disease severity scores. Clinical outcomes were worse for patients in the advanced AKI group when they had longer ICU stays and a higher 90-day mortality rate, even after discharge.

Relationship between biomarker levels and advanced AKI {#Sec12}
------------------------------------------------------

We compared urinary biomarker levels between patients with and without advanced AKI (patients without AKI or patients with stage 1 AKI): the normalized urine biomarker data were transformed logarithmically to avoid the interference of numbers in the extreme and to approximate normal distribution in the analyses (Fig. [1](#Fig1){ref-type="fig"}). At 3 h post-surgery, normalized uHJV (*p* = 0.006), and uKIM-1 (*p* = 0.019) levels in the patients with advanced AKI were significantly higher than those without advanced AKI. Moreover, considerably higher levels of uHJV and uKIM-1 were observed at 6 and 12 h post-surgery. However, there were no significant differences in the uNGAL, uα-GST and uπ-GST levels between the patients with and without advanced AKI at these sequential time points. All biomarkers analyzed by Friedman two-way ANOVA (HJV, KIM-1, NGAL, α-GST and π-GST) were significantly different (all *p* \<  0.05) between the no AKI/stage 1 AKI and the stage 2/3 AKI groups at each of the time points of 0, 3, 6, 12 and 24 h after cardiovascular surgery.Fig. 1Urinary levels of five biomarkers after cardiovascular surgery. The vertical box represents the 25th percentile (bottom line), median (middle line) and 75th percentile (top line) values, whereas the vertical bars represent the intervals between maximum and minimum values. **a** Creatinine-normalized urinary hemojuvelin (uHJV). **b** Creatinine-normalized urinary kidney injury molecule-1 (uKIM-1). **c** Creatinine-normalized urinary neutrophil gelatinase-associated lipocalin (uNGAL). **d** Creatinine-normalized urinary α-glutathione S-transferase (uα-GST). **e** Creatinine-normalized urinary π-glutathione S-transferase (uπ-GST). \**p* \< 0.05. AKI, acute kidney injury

Urinary biomarkers and the prediction of advanced AKI {#Sec13}
-----------------------------------------------------

Among the patients who subsequently developed advanced AKI, the, uHJV biomarker had the highest AUC values, particularly at 12 h post-surgery. Following normalization with urinary creatinine concentration, the predictive ability of several urinary biomarkers was improved, especially normalized uHJV at 12 h post-surgery (Table [2](#Tab2){ref-type="table"}). When compared to serum creatinine, normalized uHJV and uKIM-1 had better performance for predicting advanced AKI at 3 and 6 h post-surgery (Additional file [1](#MOESM1){ref-type="media"}: Table S1 and Fig. [1](#Fig1){ref-type="fig"}). The combined panel of normalized uHJV and uKIM-1 at 3 h post-surgery had the largest AUC (AUC = 0.898, 95% CI 0.80--0.96) compared to any of the other two or three biomarker combinations (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). This combination had a positive predictive value of 42%, negative predictive value of 100%, sensitivity of 100% and specificity of 70%. The GAM plot was generated thereafter and demonstrated positive correlation between increased normalized uHJV and uKIM-1 at 3 h post-surgery and the risk of developing advanced AKI. The cutoff value 2.346 ng/mL for normalized uHJV and 0.047 ng/mL for normalized uKIM-1 performed best to predict advanced AKI (Additional file [1](#MOESM1){ref-type="media"}: Figure S2).Table 2Area under the receiver-operating characteristic curve at each time point for urinary biomarkers with and without normalization to urinary creatinine for predicting advanced acute kidney injuryUrinary BiomarkersTime after enrollmentAUC95% CIUrinary biomarkersTime after enrollmentAUC95% CIuHJVHour 30.7930.709 to 0.862Normalized uHJVHour 30.8330.753 to 0.895Hour 60.8020.720 to 0.869Hour 60.8080.726 to 0.874Hour 120.8130.683 to 0.907Hour 120.8410.715 to 0.927Hour 240.6870.542 to 0.809Hour 240.7190.575 to 0.835uKIM-1Hour 30.6700.549 to 0.776Normalized uKIM-1Hour 30.8190.710 to 0.900Hour 60.6640.543 to 0.771Hour 60.7870.675 to 0.875Hour 120.6020.451 to 0.741Hour 120.8310.695 to 0.923Hour 240.5440.391 to 0.692Hour 240.7720.625 to 0.882uNGALHour 30.7110.621 to 0.790Normalized uNGALHour 30.7070.617 to 0.787Hour 60.7540.667 to 0.828Hour 60.6910.600 to 0.772Hour 120.6600.517 to 0.785Hour 120.7450.607 to 0.855Hour 240.6400.493 to 0.769Hour 240.6910.546 to 0.813uα-GSTHour 30.5040.419 to 0.589Normalized uα-GSTHour 30.5560.470 to 0.639Hour 60.5230.437 to 0.608Hour 60.540.454 to 0.624Hour 120.5730.487 to 0.656Hour 120.610.524 to 0.691Hour 240.6330.547 to 0.713Hour 240.5420.456 to 0.627uπ-GSTHour 30.6690.584 to 0.745Normalized uπ-GSTHour 30.5470.462 to 0.631Hour 60.7790.702 to 0.845Hour 60.5910.505 to 0.673Hour 120.5860.500 to 0.668Hour 120.5940.508 to 0.676Hour 240.6310.545 to 0.710Hour 240.5480.462 to 0.632*AUC* area under the receiver-operating characteristic curve, *CI* confidence interval, *uHJV* urinary hemojuvelin, *uKIM-1* urinary kidney injury molecule-1, *uNGAL* urinary neutrophil gelatinase-associated lipocalin, *uα-GST* urinary α-glutathione S-transferases, *uπ-GST* urinary π-glutathione S-transferasesTable 3Logistic regression analysis with variables available for predicting advanced acute kidney injury and model accuracy after combining urinary biomarkersModelAUC (95% CI)*p* ^b^Hour 3 Normalized uHJV0.833 (0.753 to 0.895)NA Normalized (uHJV + uKIM-1) ^a,c^0.898 (0.804 to 0.957)0.468 Normalized (uHJV + uNGAL)0.831 (0.751 to 0.893)0.274 Normalized (uKIM-1 + uNGAL)0.862 (0.760 to 0.932)0.943 Normalized (uHJV + uKIM-1 + uNGAL)0.897 (0.803 to 0.956)0.496Hour 6 Normalized uHJV0.808 (0.726 to 0.874)NA Normalized (uHJV + uKIM-1)0.827 (0.719 to 0.906)0.785 Normalized (uHJV + uNGAL)0.808 (0.726 to 0.874)1.00 Normalized (uKIM-1 + uNGAL)0.816 (0.707 to 0.898)0.712 Normalized (uHJV + uKIM-1 + uNGAL)0.834 (0.728 to 0.912)0.634Hour 12 Normalized uHJV0.841 (0.715 to 0.927)NA Normalized (uHJV + uKIM-1)0.890 (0.766 to 0.962)0.332 Normalized (uHJV + uNGAL)0.850 (0.725 to 0.933)0.706 Normalized (uKIM-1 + uNGAL)0.866 (0.736 to 0.947)0.819 Normalized (uHJV + uKIM-1 + uNGAL)0.892 (0.769 to 0.963)0.311Hour 24 Normalized uKIM-10.772 (0.625 to 0.882)NA Normalized (uKIM-1 + uHJV)0.848 (0.711 to 0.936)0.137 Normalized (uKIM-1 + uNGAL)0.826 (0.686 to 0.921)0.230 Normalized (uHJV + uNGAL)0.730 (0.587 to 0.844)0.567 Normalized (uKIM-1 + uHJV + uNGAL)0.855 (0.720 to 0.941)0.085*AUC* area under the receiver-operating characteristic curve, *CI* confidence interval, *NA* not applicable, *uHJV* urinary hemojuvelin, *uKIM-1* urinary kidney injury molecule-1, *uNGAL* urinary neutrophil gelatinase-associated lipocalin^a^Hosmer-Lemeshow goodness of fit test: *p* = 0.541 for the best prediction model^b^Compared with normalized uHJV at hour 3, hour 6 and hour 12 and normalized uKIM-1 at hour 24^c^Best prediction model (greatest AUC)Fig. 2Receiver-operating characteristic (ROC) curves for the best prediction model for advanced acute kidney injury. The best biomarker panel combination alone (thick dashed line), clinical risk prediction model alone (thin dashed line) and combination of the clinical risk prediction model and combined biomarker panel (solid line) are shown at hour 3 (**a**), hour 6 (**b**), hour 12 (**c**) and hour 24 (**d**). The clinical risk prediction model is calculated from Liano's score. The area under the ROC curve (AUC) values and 95% confidence intervals (CIs) are also shown

Adding urinary biomarkers to clinical risk prediction models {#Sec14}
------------------------------------------------------------

In combining the predictive ability of novel biomarkers and various clinical scoring systems for AKI, we found that the greatest AUC was observed with the combination of Liano's AKI score and the panel of normalized uHJV and uKIM-1 at 3 h after surgery, with an AUC of 0.931 to predict advanced AKI. This panel had a greater AUC value than other combinations of biomarkers at 3, 6, 12, or 24 h after surgery (Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Table 4Logistic regression analysis with variables available for predicting advanced acute kidney injury and model accuracy after combining clinical models with urinary biomarkersModelAUC (95% CI)*p* ^b^Liano's score0.619 (0.536 to 0.698)Cleveland score0.493 (0.410 to 0.576)SOFA score0.700 (0.619 to 0.773)Hour 3 Normalized uHJV0.833 (0.753 to 0.895)NA Liano's + normalized uHJV0.817 (0.736 to 0.882)0.672 Cleveland + normalized uHJV0.808 (0.726 to 0.874)0.662 SOFA + normalized uHJV0.786 (0.701 to 0.856)0.419  Normalized (uHJV + uKIM-1)0.898 (0.804 to 0.957)0.468 Liano's + normalized (uHJV + uKIM-1)^a,c^0.931 (0.846 to 0.977)0.206 Cleveland + normalized (uHJV + uKIM-1)0.883 (0.785 to 0.946)0.817 SOFA + normalized (uHJV + uKIM-1)0.876 (0.776 to 0.942)0.811Hour 6 Normalized uHJV0.808 (0.726 to 0.874)NA Liano's + normalized uHJV0.791 (0.707 to 0.860)0.653 Cleveland + normalized uHJV0.769 (0.683 to 0.841)0.544 SOFA + normalized uHJV0.759 (0.672 to 0.833)0.426 Normalized (uHJV + uKIM-1 + uNGAL)0.834 (0.728 to 0.912)0.634 Liano's + normalized (uHJV + uKIM-1 + uNGAL)0.867 (0.766 to 0.935)0.334 Cleveland + normalized (uHJV + uKIM-1 + uNGAL)0.817 (0.709 to 0.899)0.985 SOFA + normalized (uHJV + uKIM-1 + uNGAL)0.812 (0.702 to 0.895)0.920Hour 12 Normalized uHJV0.841 (0.715 to 0.927)NA Liano's + normalized uHJV0.834 (0.707 to 0.922)0.879 Cleveland + normalized uHJV0.892 (0.776 to 0.960)0.429 SOFA + normalized uHJV0.834 (0.705 to 0.923)0.656 Normalized (uHJV + uKIM-1 + uNGAL)0.892 (0.769 to 0.963)0.311 Liano's + normalized (uHJV + uKIM-1 + uNGAL)0.923 (0.808 to 0.980)0.151 Cleveland + normalized (uHJV + uKIM-1 + uNGAL)0.916 (0.800 to 0.976)0.281 SOFA + normalized (uHJV + uKIM-1 + uNGAL)0.914 (0.795 to 0.975)0.302Hour 24 Normalized uKIM-10.772 (0.625 to 0.882)NA Liano's + normalized uKIM-10.799 (0.655 to 0.902)0.488 Cleveland + normalized uKIM-10.765 (0.617 to 0.877)0.737 SOFA + normalized uKIM-10.797 (0.650 to 0.902)0.587 Normalized (uKIM-1 + uHJV + uNGAL)0.855 (0.720 to 0.941)0.085 Liano's + normalized (uKIM-1 + uHJV + uNGAL)0.882 (0.753 to 0.958)0.030 Cleveland + normalized (uKIM-1 + uHJV + uNGAL)0.863 (0.729 to 0.946)0.096 SOFA + normalized (uKIM-1 + uHJV + uNGAL)0.869 (0.735 to 0.951)0.082*AUC* area under the receiver-operating characteristic curve, *CI* confidence interval, *SOFA* score Sequential Organ Failure Assessment score, *uHJV* urinary hemojuvelin, *uKIM-1* urinary kidney injury molecule-1, *uNGAL* urinary neutrophil gelatinase-associated lipocalin^a^Hosmer-Lemeshow goodness of fit test: *p* = 0.481 for the best prediction model^b^Compared with normalized uHJV at hour 3, hour 6 and hour 12 and normalized uKIM-1 at hour 24^c^Best prediction model (greatest AUC), combined clinical model (Liano's score) with biomarkers

We assessed reclassification and evaluated any improvement in detection of advanced AKI events. The combination of the creatinine-normalized uHJV and uKIM-1 biomarker panel with the Liano's score led to a significant increase in risk stratification (total NRI = 1.149; *p* \< 0.001). The majority of this effect came from those with advanced AKI events (NRI event = 0.538; *p* \< 0.001), whereas the NRI non-event was 0.610 (95% CI, *p* \< 0.001) (NRI reclassification table and proportion was shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2). Simultaneously, the total integrated discrimination improvement (IDI) was significant at 0.383 (95% CI, 0.25--0.52; *p* \< 0.001). The combination of normalized uHJV and uKIM-1 with the Liano's score was also significant for NRI and IDI reclassification in forecasting advanced AKI at 6, 12, and 24 h post-surgery (Table [5](#Tab5){ref-type="table"}).Table 5Discriminative improvement of combined biomarkers added to Liano's score for prediction of advanced acute kidney injuryModelAUC (95% CI)*p* ^a^NRI^b^ (95% CI)*p* ^c^IDI (95% CI)*p*Hour 3 Normalized (uHJV + uKIM-1)0.898 (0.804 to 0.957)NA Liano's + normalized (uHJV + uKIM-1)^d^0.931 (0.846 to 0.977)0.3301.149 (0.76 to 1.53)\<  0.0010.383 (0.25 to 0.52)\<  0.001Hour 6 Normalized (uHJV + uKIM-1 + uNGAL)0.834 (0.728 to 0.912)NA Liano's + normalized (uHJV + uKIM-1 + uNGAL)0.867 (0.766 to 0.935)0.4991.030 (0.64 to 1.41)\<  0.0010.343 (0.21 to 0.48)\<  0.001Hour 12 Normalized (uHJV + uKIM-1 + uNGAL)0.892 (0.769 to 0.963)NA Liano's + normalized (uHJV + uKIM-1 + uNGAL)0.923 (0.808 to 0.980)0.3440.831 (0.40 to 1.27)\< 0.0010.353 (0.19 to 0.52)\<  0.001Hour 24 Normalized (uKIM-1 + uHJV + uNGAL)0.855 (0.720 to 0.941)NA Liano's + normalized (uKIM-1 + uHJV + uNGAL)0.882 (0.753 to 0.958)0.2881.162 (0.81 to 1.52)\< 0.0010.387 (0.27 to 0.51)\<  0.001*AUC* area under the receiver-operating characteristic curve, *CI* confidence interval, *IDI* integrated discrimination improvement, *NRI* net reclassification improvement, *uHJV* urinary hemojuvelin, *uKIM-1* urinary kidney injury molecule-1, *uNGAL* urinary neutrophil gelatinase-associated lipocalin^a^Compared with normalized (uHJV + uKIM-1) at hour 3, normalized (uHJV + uKIM-1 + uNGAL) at hour 6, normalized (uHJV + uKIM-1 + uNGAL) at hour 12 and normalized (uKIM-1 + uHJV + uNGAL) at hour 24^b^The ability of a risk marker to more accurately stratify individuals into higher or lower risk categories was investigated by NRI. We reclassified the patients who had subsequent advanced acute kidney injury (AKI) or who did not by using a priori risk categories of 0--12%, 12--30% and \> 30% for the risk of advanced AKI^c^The *p* value for increase in NRI in a model with urinary biomarkers combined with Liano's score compared with urinary biomarkers alone^d^Best prediction model (greatest AUC), combined clinical model (Liano's score) with biomarkers
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The combined panel of normalized uHJV and uNGAL at 3 h post-surgery had strong predictive ability for 90-day mortality rate after hospital discharge (AUC = 0.896) and the best predictive ability for composite outcomes (AUC = 0.905). The predictive ability for composite outcomes further improved after combination with Liano's score (AUC = 0.943) (Additional file [1](#MOESM1){ref-type="media"}: Table S3). Given the potential for collinearity between some of the biomarkers, we performed an unsupervised cluster analysis to determine the relationship of the biomarkers to advanced AKI (Fig. [3](#Fig3){ref-type="fig"}). The unsupervised clustering resulted in groupings similar to functional groupings for some of the biomarkers. For instance, uHJV and uKIM-1 in the group associated with proximal tubular dysfunction were clustered in the near group, nearest to "advanced AKI", and may explain their strong predictive ability for advanced AKI. Overall, the correlation within each group was stronger for biomarkers that had better predictive ability.Fig. 3Urinary biomarker concentrations related to advanced acute kidney injury (AKI). The creatinine-normalized biomarker concentrations were analyzed by unsupervised clustering to determine their relationship to advanced AKI. Full-length view of the cluster diagram has cases orientated along the vertical axis and biomarkers orientated along the horizontal axis. α-GST, α-glutathione S-transferase; π-GST, π-glutathione S-transferase; HJV, hemojuvelin; KIM-1, kidney injury molecule-1; NGAL, neutrophil gelatinase associated lipocalin; UCr, urinary creatinine

Discussion {#Sec16}
==========

In this prospective multicenter observational study, we have shown that the combined biomarker panel of creatinine-normalized uHJV and uKIM-1 at 3 h after cardiovascular surgery had the strongest predictive ability for the development of advanced AKI and composite outcomes. This predictive ability was increased further after combination with Liano's score. The combination of clinical models and biologic biomarkers could better anticipate the future development of advanced AKI in the early postoperative period, suggesting future clinical outcomes.

The combination of uHJV and uKIM-1, both markers of structural kidney injury, provided added value to the traditional clinical AKI score in forecasting the risk of advanced AKI. Consequently, combination approaches could account for different time courses of biomarker release or could reflect different pathophysiological mechanisms \[[@CR41]\]. HJV, a glycophosphatidylinositol (GPI)-linked membrane protein, is highly expressed in liver and skeletal muscles. The molecular weight of HJV is 42 kDa for the soluble form (sHJV) \[[@CR42]\], and can be passed through glomerular filtration and reabsorbed by the renal tubules \[[@CR8]\]. Increased iron content in the kidney and urine is observed in human and animal models of AKI \[[@CR43]\], and increased iron load can induce renal tubular cell injury \[[@CR44]\]. There is evidence that the increased expression of the hemojuvelin-hepcidin-ferroportin pathway is an intrinsic response to iron overload conditions during AKI. Therefore, uHJV has the potential to be an early AKI biomarker in response to iron homeostasis during AKI, which may explain the temporal relationship between uHJV and its predictive capacity. In this study, we showed that the novel biomarker of HJV can predict AKI after cardiac surgery. This finding reinforced our previous finding, in which high urinary HJV levels were observed in patients after cardiac surgery and rhabdomyolysis-related AKI. Although HJV is highly expressed in liver, the post-surgery liver function was not significantly different between the no AKI/stage 1 AKI and the stage 2/3 AKI groups This result suggested higher HJV concentration in patients with advanced AKI was mainly from kidney injury. According to our animal model, the elevation of urinary HJV in acute tubular necrosis should be originally from filtration after renal tubular destruction rather than the liver (see Additional file [1](#MOESM1){ref-type="media"}) \[[@CR8]\].

Kidney injury molecule-1 (KIM-1), a 38.7-kDa transmembrane protein with immunoglobulin-like and mucin domains in its ectodomain, is a novel biomarker for renal proximal tubule injury and could play a role in tubulo-interstitial damage \[[@CR45]\]. In addition to being a biomarker of AKI, KIM-1 could also play a role in renal recovery and tubular regeneration after AKI \[[@CR46]\]. However, because increased urinary KIM-1 concentration can indicate either injury or the repair response to injury, KIM-1 by itself may not be a suitable marker for early prediction of AKI whereas the combination of KIM-1 with other injury markers may be highly useful. In support of this hypothesis, our result was consistent with a study investigating biomarker combinations for prediction of AKI following cardiac surgery \[[@CR14]\], whereby KIM-1 in combination with another biomarker had the best predictive value for severe AKI.

We further showed that the combination of a panel of biomarkers and Liano's AKI score may be beneficial in providing additional information with respect to the risk of AKI severity and other adverse clinical outcomes. Due to the heterogeneous causes of AKI and underlying comorbidities, the use of biomarkers and clinical disease severity scores to predict renal injury seems reasonable and actually did have better accuracy \[[@CR17]\]. For increased accuracy and added predictive ability beyond the AUC value, the biomarker and clinical score combination model was supported by net reclassification improvement (NRI) and integrated discrimination improvement (IDI) values. The NRI and IDI represent modern, more sensitive statistical methods to reclassify model improvement from the use of a biomarker with an existing clinical model. Urinary HJV and uKIM-1 had the unique ability to improve the NRI for both events and non-events and augmented the AUC value compared with use of a clinical model alone and thus, uHJV and uKIM-1 may serve as an ideal biomarker panel to help early detection of advanced AKI.

Biomarkers predicting advanced AKI will allow future clinical trials in AKI intervention to be targeted to those patients at highest risk of disease progression, which would be far more efficient in terms of costs and resources \[[@CR47]\]. The majority of patients (28/46, 60.9% in this study) who developed AKI after cardiovascular surgery had stage 1 AKI and this spontaneously resolved. The ability to distinguish those patients at highest risk of severe outcomes will be crucial as nephrologists and intensivists conduct more clinical trials in the treatment of AKI \[[@CR48]\]. Given the clinical uncertainty and high complexity of medical decision-making around this issue (e.g., timing and duration of renal replacement therapy, placement of permanent access and follow up), any method that provides a modest improvement in clinical prediction could have clinical importance. We endeavor to find the biomarkers and clinical severity score to determine which patients will develop advanced AKI, and help to improve clinical decision-making - such as earlier or delayed dialysis \[[@CR4], [@CR49]\], guiding decision-making, patient counseling and facilitating enrollee selection in interventional trials of AKI.

There were several limitations to our study. First, because of the limited sample size, the statistical significance may be improved after recruiting more patient samples. Second, only those patients undergoing cardiovascular surgery were included in this study and consequently other serious causes of AKI, such as sepsis or drug-induced AKI, are not represented. The results of our study could add to the value of AKI prediction after generalized cardiovascular surgery, and further large prospective studies are necessary to validate our results. Third, about 3% of urinary biomarker data were lost due to anuria at 12 and 24 h post-surgery. In addition, we did not obtain urine samples during surgery. Tubular injury may occur 30 min after commencing cardiopulmonary bypass in cardiac surgery with a peak immediately following completion of cardiopulmonary bypass \[[@CR50]\]. However, our results clearly showed these markers had their peak level at 3 h after surgery and could predict advanced AKI. For clinical practice, urine collection after surgery was more feasible than collection during surgery. Finally, other urinary biomarkers, such as IL-18 and L-fatty acid binding protein, which also have promising results for predicting AKI, were not examined \[[@CR51], [@CR52]\].

Our study also has several strengths. First, this was a large multicenter prospective study and included a homogenous (post-cardiovascular surgery) patient population. Second, our study contained five biomarkers (including markers of proximal and distal tubular injury) and tested urine samples obtained in the ICU at 0, 3, 6, 12 and 24 h after completion of surgery, which allowed exploration of the dynamic changes in their urinary concentrations and provided more comprehensive and credible results than previous studies \[[@CR12], [@CR53], [@CR54]\]. Finally, this is, to our best knowledge, the first study using panels of urinary biomarkers in combination with clinical risk scores to focus on prediction of advanced AKI after cardiovascular surgery. Urinary biomarkers can lead to more accurate diagnosis of AKI and can further be used for recruitment of more homogenous patient populations when implementing a clinical trial \[[@CR55]\].

Conclusions {#Sec17}
===========

In conclusion, our results indicate that creatinine-normalized urinary biomarkers, particularly HJV and KIM-1 in combination, can improve the clinical predictive ability of Liano's score for advanced AKI and composite outcomes at an early time point after cardiovascular surgery. Risk prediction utilizing both biomarkers and clinical AKI score may enhance critical care and aid in forecasting the prognosis of postoperative patients. Larger prospective studies are necessary to confirm our observations and to validate the predictive panel for assessing clinical AKI.
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Additional file 1:Supplementary methods: brief introduction of HJV, KIM-1, uNGAL, α-GST, π-GST; Liano's score, National Taiwan University Study Group on Acute Renal Failure (NSARF) introduction and inotropic equivalents (IE). **Table S1.** Area under the receiver-operating characteristic curve (AUC) for normalized uHJV, uKIM-1 and serum creatinine for predicting advanced AKI at 3 and 6 h post-surgery. **Table S2.** Number and percent reclassified in advanced AKI prediction comparing initial model (Normalized \[uHJV + uKIM-1\]) to updated model (Liano's + Normalized \[uHJV + uKIM-1\]) at 3 h post-surgery. **Table S3.** Logistic regression analysis with variables available for predicting 90 days mortality after hospital discharge and composite outcomes. **Figure S1.** Receiver-operator characteristic curves for normalized uHJV, uKIM-1 and serum creatinine for predicting advanced AKI at 3 and 6 h post-surgery. **Figure S2.** Generalized additive models (GAM) plot for the probability of advanced AKI for normalized urinary HJV and KIM-1 at T3 (3 h post-surgery). (DOCX 723 kb)
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